ungelesene_bettlek
Bluelighter
so since only a few years the psychedelic community has experience with the NBOMe-2C-X series of psychedelics, which is pose some quite special problems to the user because of their high potency, which makes the dosage difficult to measure, and their oral inactivity (it seems to me it is still widely undecided which parenteral ROA is the best for this group). yet, they have gained their fanbase, so I guess there must be something very unique about them (I haven't tried them myself yet, but I surely plan to do so one day). and now, only a few month ago, a new subgroup spread of, the NBOH-2C-X compounds lacking one methyl group. the reason for this new development is solely to get one step ahead in the law again (correct me if I'm wrong), and this argument is actually only valid in a handful of legislations - but for some reasons, the british one is one of those few, and our English fellowmen seem to be especially fond about their grey marked psychedelics.
when one looks at the structure-activity-relationship of 5HT2A-psychedelics, one of the most important rules one has to accept is that there are surprisingly few rules, and one has to expect the unexpected, for example, I still know of no rule of thumb to conclude from the properties of a psychedelic two-carbon-chain phenethylamine to the properties of the corresponding amphetamine. who could have e.g. guesses from the beginning that 2C-E is a much more powerful psychedelic than 2C-D, while with DOM and DOET it is just the other way round?
now you can surely already guess in what direction my question goes: how is the interrelationship between a NBOMe-2C-X compound to its corresponding NBOH-2C-X: I have already read that the latter ones are a bit less potent per weight, and a bit shorter-lived; but apart from that, how strong is the qualitative difference in the experience that this little missing methyl group makes? do we again get completely new compounds with a completely different headspace, or is this difference little enough that one can say that the two corresponding trips are pretty similar, at least if one doesn't look to close?
when one looks at the structure-activity-relationship of 5HT2A-psychedelics, one of the most important rules one has to accept is that there are surprisingly few rules, and one has to expect the unexpected, for example, I still know of no rule of thumb to conclude from the properties of a psychedelic two-carbon-chain phenethylamine to the properties of the corresponding amphetamine. who could have e.g. guesses from the beginning that 2C-E is a much more powerful psychedelic than 2C-D, while with DOM and DOET it is just the other way round?
now you can surely already guess in what direction my question goes: how is the interrelationship between a NBOMe-2C-X compound to its corresponding NBOH-2C-X: I have already read that the latter ones are a bit less potent per weight, and a bit shorter-lived; but apart from that, how strong is the qualitative difference in the experience that this little missing methyl group makes? do we again get completely new compounds with a completely different headspace, or is this difference little enough that one can say that the two corresponding trips are pretty similar, at least if one doesn't look to close?
